Reviva Pharmaceuticals’ (RVPH) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital reaffirmed their buy rating on shares of Reviva Pharmaceuticals (NASDAQ:RVPH) in a report released on Tuesday,Benzinga reports. They currently have a $15.00 price target on the stock.

RVPH has been the topic of a number of other reports. Roth Mkm assumed coverage on shares of Reviva Pharmaceuticals in a research report on Friday, January 10th. They set a “buy” rating and a $7.00 target price on the stock. Maxim Group upgraded shares of Reviva Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a report on Friday, January 10th. Roth Capital upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Friday, January 10th. Finally, EF Hutton Acquisition Co. I upgraded Reviva Pharmaceuticals to a “strong-buy” rating in a research note on Monday, September 23rd. Five analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat.com, Reviva Pharmaceuticals has a consensus rating of “Buy” and an average target price of $11.40.

Reviva Pharmaceuticals Stock Performance

Shares of NASDAQ:RVPH opened at $1.89 on Tuesday. The business’s 50-day simple moving average is $1.70 and its 200 day simple moving average is $1.33. The company has a market cap of $63.20 million, a P/E ratio of -1.70 and a beta of -0.12. Reviva Pharmaceuticals has a one year low of $0.60 and a one year high of $4.83.

Hedge Funds Weigh In On Reviva Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. EMC Capital Management boosted its holdings in shares of Reviva Pharmaceuticals by 142.0% during the fourth quarter. EMC Capital Management now owns 44,535 shares of the company’s stock valued at $81,000 after acquiring an additional 26,134 shares during the period. Drive Wealth Management LLC acquired a new stake in shares of Reviva Pharmaceuticals in the 4th quarter worth about $36,000. Finally, Geode Capital Management LLC lifted its position in Reviva Pharmaceuticals by 17.9% in the 3rd quarter. Geode Capital Management LLC now owns 278,496 shares of the company’s stock valued at $401,000 after purchasing an additional 42,376 shares during the last quarter. Institutional investors and hedge funds own 63.18% of the company’s stock.

About Reviva Pharmaceuticals

Reviva Pharmaceuticals Holdings, Inc, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases. The company's lead product candidate comprises brilaroxazine (RP5063) for the treatment of various neuropsychiatric indications, including schizophrenia, bipolar disorder, major depressive disorder, attentiondeficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia and Alzheimer's disease, and Parkinson's disease psychosis; in clinical development respiratory indications, such as pulmonary arterial hypertension and idiopathic pulmonary fibrosis; and in preclinical development for the treatment of psoriasis.